TIDMCPT
RNS Number : 3281T
Concepta PLC
14 November 2019
Concepta PLC
("Concepta" or the "Company")
Board Appointments
Concepta PLC (AIM: CPT), the innovative UK personalised
healthcare company and developer of the proprietary self-test
platform ("myLotus(R)") the most accurate home-use fertility
tracking and pregnancy testing system available on the U.K. market,
announces the appointments of Penelope ("Penny") McCormick as Chief
Executive and Lyn Rees as a Non-Executive Director.
Penny is a marketing specialist and Managing Director with
extensive commercial leadership experience in the medical devices
and women's healthcare sectors.
Penny previously led BBI Healthcare Limited (part of BBI Group),
where her primary focus was developing a commercial strategy to
secure the market-leading position for Balance Activ, the company's
flagship bacterial vaginosis treatment. This included the securing
of a GBPmulti-million licence agreement with Bayer, the integration
of the newly acquired Swedish manufacturing facility, and portfolio
expansion to champion the category growth of women's 'over the
counter' healthcare within U.K. retail. These successful launches
into U.K. multiple grocery and high street pharmacy featured
medical devices created to support women through various life
stages including conception and menopause.
Her 12 year tenure at the BBI Group also saw delivery of a
global marketing and integration strategy across the group's
various entities through a rapid growth phase. Penny delivered
strong financial growth, market impact, and developed skilled teams
across OTC and B2B in highly competitive and margin-driven
regulated markets.
Prior to joining BBI, Penny began her marketing career as a PR
Manager at one of Wales' leading integrated agencies, followed by
honing a specialism in FMCG within the licensed confectionery
category, with a focus on growth within U.K. multiple grocery
retailers. She holds an Honours degree in Journalism from Cardiff
University.
Lyn is a seasoned executive in global healthcare and IVD
markets. Prior to joining AIM-quoted Yourgene Health plc as CEO
(formerly Premaitha Health plc), Lyn was Group CEO at British
Biocell International (now BBI Group) for over 9 years.
He began that role at BBI Group following the acquisition of BBI
Holdings by Alere in 2008, and in his time he oversaw the doubling
of revenue growth and developed an accountable and highly effective
senior management team with clear focus on innovation, commercial
delivery, compliance and operational efficiency. He has a
demonstrable track record of organic and acquisitive growth in the
global Healthcare market.
Before this role, he spent several years as the Managing
Director and founder of BBI Healthcare in 2006 following the
successful purchase of the GlucoGel product. He first began his
business career as the European Marketing Manager at Shimano Europe
BV. Lyn holds a degree in Business Studies from the University of
Wales.
Enquiries:
Concepta plc www.conceptaplc.com
Adam Reynolds, Non-Executive Chairman Mob: +44 (0) 7785 908 158
SPARK Advisory Partners Limited Tel: +44 (0)20 368 3550
(NOMAD)
Neil Baldwin / Mark Brady
Novum Securities (Broker) Tel: +44 (0)20 7399 9400
Colin Rowbury
Walbrook PR Ltd (Media & Investor Tel: +44 (0)20 7933 8780
Relations)
Paul McManus concepta@walbrookpr.com
About Concepta PLC (www.conceptaplc.com)
Concepta PLC is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus(R), targeted at
the personalized mobile health market with a primary focus on
hormone testing and increasing a woman's chances of naturally
getting pregnant and to provide insight to unexplained
infertility.
myLotus(R) is currently the only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus(R) is to empower women
to better understand their hormone levels and menstrual cycle and
help women conceive naturally by identifying their window of
fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus(R)
and has launched its first product in the UK. The Company is
preparing plans to roll-out across the core EU countries in
2019.
myLotus(R) is expected to be beneficial to users who have been
unable to conceive after 6 months of trying. This highly motivated
target group of women won't typically be offered medical
intervention until after 12 months of unsuccessfully trying to
conceive, with IVF not usually offered until after two years of
trying to conceive. Research indicates couples start to take
positive action ahead of this time typically with little medical
support to help them do so.
The following disclosures are made in line with the AIM Rules
for Companies:
Penny's full name is Penelope Jane McCormick, she is 44 years
old.
Current directorships/partnerships:
Hope Rescue
Directorships and partnerships held within the last five
years:
BBI Healthcare Limited
Shareholding: Ms McCormick holds no shares in the Company.
Save for the information set out above, there are no further
disclosures to be made in accordance with Rule 17, Schedule 2(g) of
the AIM Rules for Companies in respect of the appointment of Ms
McCormick.
Lyn's full name is Lyn Dafydd Rees, he is 46 years old.
Current directorships/partnerships:
Yourgene Health PLC
Premaitha Limited
Delta Diagnostics (UK) LTD
F & H Baxter (Holdings) Limited
Yourgene Health Singapore Co. Pty Ltd
Yourgene Health Taiwan Ltd
Directorships and partnerships held within the last five
years:
BBI Diagnostics UK 1 Limited
BBI Diagnostics UK 2 Limited
BBI Diagnostics UK 3 Limited
BBI Diagnostics UK 4 Limited
BBI Diagnostics UK 5 Limited
BBI Solutions OEM Limited
BBI Resources Limited
Eagle SPV 3 Limited
BBI Acquisition Limited
Eagle SPV 2 Limited
BBI Group Holding Limited
BBI Diagnostics Group 2 PLC
BBI Animal Health Limited
Alere BBI Holdings Limited
Alere UK Subco Limited
Adam Biotechnology Limited
Biozyme Holdings Limited
Cambridge Bio-Nutritional Limited
Novarum DX Limited
Alchemy Laboratories Ltd
BBI Detection Limited
BBI Healthcare Limited
BBI Enzymes (USA) Limited
BBI Enzymes (UK) Limited
British Biocell International Limited
BBI Diagnostics Group Limited
BBI Enzymes Limited
Scipac Limited
Shareholding: Mr Rees holds no shares in the Company.
Save for the information set out above, there are no further
disclosures to be made in accordance with Rule 17, Schedule 2(g) of
the AIM Rules for Companies in respect of the appointment of Mr
Rees.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOABJBFTMBMBBRL
(END) Dow Jones Newswires
November 14, 2019 02:01 ET (07:01 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024